Allianz Asset Management
ELVN icon

Allianz Asset Management’s Enliven Therapeutics ELVN Stock Holding History

Allianz Asset Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.64M Buy
+52,008
New +$2.21M ﹤0.01% 1650

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Allianz Asset Management's ELVN Position: Q2 2026 in Review

Allianz Asset Management opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 52,008 shares worth $2.64M. The stake represents ﹤0.01% of the portfolio and ranks #1650 among its holdings.

212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Allianz Asset Management held 52,008 shares of Enliven Therapeutics worth $2.64M as of Q2 2026.
  • Enliven Therapeutics was a new Allianz Asset Management position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1650 holding.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.